

Name of Journal: *World Journal of Gastroenterology*

Manuscript NO: 42259

Manuscript Type: ORIGINAL ARTICLE

Retrospective Study

Δ 4-3-oxosteroid-5 β -reductase deficiency: Responses and long-term outcomes from oral bile acid therapy

Zhang MH *et al.* AKR1D1 deficiency: Oral bile acid therapy

Mei-Hong Zhang, Kenneth DR Setchell, Jing Zhao, Jing-Yu Gong, Yi Lu, Jian-She Wang

Abstract

BACKGROUND

Disorders of primary bile acid synthesis may be life-threatening if undiagnosed, or not treated with primary bile acid replacement therapy. To date, there are few reports on the management and follow-up of patients with the Δ 4-3-oxosteroid 5 β -reductase (AKR1D1) deficiency. The retrospective analysis of the responses to oral bile acid replacement therapy with chenodeoxycholic acid (CDCA) in patients with this bile acid synthesis disorder we hypothesized will increase our understanding of the disease progression and permit evaluation of this treatment regimen as an alternative to the Food and Drug Administration (FDA) approved drug cholic acid

Match Overview

1	Internet 70 words crawled on 13-Jun-2017 www.wjgnet.com	1%
2	Internet 21 words crawled on 28-Dec-2017 www.dovepress.com	<1%
3	Internet 19 words crawled on 07-Apr-2018 bmcgastroenterol.biomedcentral.com	<1%
4	Internet 15 words www.jci.org	<1%
5	Crossref 14 words James E. Heubi, Kevin E. Bove, Kenneth D.R. Setchell. "Oral Cholic Acid Is Efficacious and Well Tolerated in Patients	<1%
6	Internet 13 words crawled on 26-Aug-2016 www.nature.com	<1%
7	Crossref 12 words Yang, Hai-Kuan, Yi-Xing Cheng, Ming-Ming Su, Yu Xiao, Min-Biao Hu, Wei Wang, and Qian Wang. "Polyoxometalate-	<1%
8	Crossref 12 words Osman Ahmad, Janaina Nogueira, James E Heubi, Kenneth D R Setchell, Ambika Ashraf. "Bile Acid Synthesis Disc ...	<1%

找到约 158 条结果 (用时 0.66 秒)

Mutations in SRD5B1 (AKR1D1), the gene encoding Δ 4-3-oxosteroid ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773813/> - 翻译此页

作者: HA Lemonde - 2003 - 被引用次数: 76 - 相关文章

Results: Mutations in the SRD5B1 gene were identified in all three children. ... Patients with genetic 5 β -reductase deficiency may respond well to treatment with ... of bile acids from cholesterol (that is, Δ^4 -3-oxosteroid 5 β -reductase deficiency). ... alanine aminotransferase (ALT) 1123 U/l, and a prolonged prothrombin time ...

Crystal Structure of Human Liver Δ 4-3-Ketosteroid 5 β -Reductase ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2423251/> - 翻译此页

作者: L Di Costanzo - 2008 - 被引用次数: 53 - 相关文章

Search term ... Crystal Structure of Human Liver Δ^4 -3-Ketosteroid 5 β -Reductase (AKR1D1) and ... or 5 β -dihydrosteroids in reactions catalyzed by steroid 5 α - or 5 β - reductase, ... AKR1D1 deficiency results in accumulation of C27 bile acid precursors ... and R261C) (20-22), is effectively treated with oral bile acid therapy (19).

(PDF) Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ...

https://www.researchgate.net/.../14495450_D4-3-Oxosteroid_5b-reductase_deficiency_F...

PDF | In some infants with liver disease, 3-oxo- Δ^4 bile acids are the major bile acids ... Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid Longterm follow up, including liver function monitoring and urine bile acid analyses, are ...

(PDF) Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4 ...

https://www.researchgate.net/.../10571391_Mutations_in_SRD5B1_AKR1D1... - 翻译此页

Mutations in SRD5B1 (AKR1D1), the gene encoding delta(4)-3-oxosteroid ... MS was cured by treatment with chenodeoxycholic acid and cholic acid; BH showed ... Patients with genetic 5beta-reductase deficiency may respond well to treatment with Long-term oral treatment with primary BA improved liver histology and ...

Human Δ 4-3-oxosteroid 5 β -reductase (AKR1D1) deficiency and ...

www.academia.edu/.../Human_Delta4-3-oxosteroid_5b-reductase_AKR1D1_def... - 翻译此页

Human Δ 4-3-oxosteroid 5 β -reductase (AKR1D1) deficiency and steroid metabolism ... All her vital

[全部](#)[新闻](#)[图片](#)[视频](#)[购物](#)[更多](#)[设置](#)[工具](#)

找到约 582 条结果 (用时 0.57 秒)

(PDF) Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ...

https://www.researchgate.net/.../14495450_D4-3-Oxosteroid_5b-reductase_deficiency_F...

PDF | In some infants with liver disease, 3-oxo-delta 4 **bile acids** are the major **bile acids** ... Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ursodeoxycholic acid **treatment** and **response** to chenodeoxycholic acid plus **cholic acid** **Longterm** follow up, including liver function monitoring and urine **bile acid** analyses, are ...

Δ 4-3-oxosteroid 5 β -reductase deficiency described in identical twins ...

https://www.researchgate.net/.../19957067_D4-3-oxosteroid_5b-reductase_d... - 翻译此页

Request PDF on ResearchGate | Δ 4-3-oxosteroid 5 β -reductase deficiency ... A new inborn error in **bile acid** synthesis, manifest in identical infant twins as ... in enzymes catalyzing key **reactions** in the formation of the primary **bile acids** ... acid synthesis defects: a life-saving **therapy** allowing a favorable **outcome** in adulthood.

Mutations in SRD5B1 (AKR1D1), the gene encoding Δ 4-3-oxosteroid ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773813/> ▾ 翻译此页

作者: HA Lemonde - 2003 - 被引用次数: 78 - 相关文章

Results: Mutations in the SRD5B1 gene were identified in all three children. ... Patients with genetic 5 β -reductase deficiency may **respond** well to **treatment** with ... of **bile acids** from cholesterol (that is, Δ^4 -3-oxosteroid 5 β -reductase deficiency). ... alanine aminotransferase (ALT) 1123 U/l), and a **prolonged** prothrombin time ...

Cholic acid for primary bile acid synthesis defects: a life ... - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/m/pubmed/30373615> - 翻译此页

Cholic acid for primary **bile acid** synthesis defects: a life-saving **therapy** ... To date there has been no report of the **effects** of this **therapy** in children reaching adulthood. ... or Δ 4-3-oxosteroid 5 β -reductase (Δ 4-3-oxo-R) (n = 2) **deficiency** confirmed ... **CONCLUSIONS:** **Oral CA therapy** is a safe and effective **long-term treatment** ...

[PDF] 205750Orig1s000 - FDA

https://www.accessdata.fda.gov/drugsatfda_.../205750Orig1s000RiskB.pdf ▾ 翻译此页

找到约 582 条结果 (用时 0.57 秒)

(PDF) Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ...

https://www.researchgate.net/.../14495450_D4-3-Oxosteroid_5b-reductase_deficiency_F...

PDF | In some infants with liver disease, 3-oxo- Δ 4 bile acids are the major bile acids ... Δ 4-3-Oxosteroid 5 β -reductase deficiency: Failure of ursodeoxycholic acid treatment and response to chenodeoxycholic acid plus cholic acid Longterm follow up, including liver function monitoring and urine bile acid analyses, are ...

Δ 4-3-oxosteroid 5 β -reductase deficiency described in identical twins ...

https://www.researchgate.net/.../19957067_D4-3-oxosteroid_5b-reductase_d... - 翻译此页

Request PDF on ResearchGate | Δ 4-3-oxosteroid 5 β -reductase deficiency ... A new inborn error in bile acid synthesis, manifest in identical infant twins as ... in enzymes catalyzing key reactions in the formation of the primary bile acids ... acid synthesis defects: a life-saving therapy allowing a favorable outcome in adulthood.

Mutations in SRD5B1 (AKR1D1), the gene encoding Δ 4-3-oxosteroid ...

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1773813/> - 翻译此页

作者: HA Lemonde - 2003 - 被引用次数: 78 - 相关文章

Results: Mutations in the SRD5B1 gene were identified in all three children. ... Patients with genetic 5 β -reductase deficiency may respond well to treatment with ... of bile acids from cholesterol (that is, Δ 4-3-oxosteroid 5 β -reductase deficiency). ... alanine aminotransferase (ALT) 1123 U/l), and a prolonged prothrombin time ...

Cholic acid for primary bile acid synthesis defects: a life ... - NCBI - NIH

<https://www.ncbi.nlm.nih.gov/m/pubmed/30373615> - 翻译此页

Cholic acid for primary bile acid synthesis defects: a life-saving therapy ... To date there has been no report of the effects of this therapy in children reaching adulthood. ... or Δ 4-3-oxosteroid 5 β -reductase (Δ 4-3-oxo-R) (n = 2) deficiency confirmed ... CONCLUSIONS: Oral CA therapy is a safe and effective long-term treatment ...

[PDF] 205750Orig1s000 - FDA

<https://www.accessdata.fda.gov/drugsatfda/.../205750Orig1s000RiskP.pdf> - 翻译此页